A Biotech ETF For Aggressive, Risk-Tolerant Investors

The biotechnology sector has been on fire thanks to news from Biogen Inc. BIIB. The FDA approved its controverisal drug that can treat Alzheimer’s Disease.

Not surprisingly, there have been big moves by many of the stocks in this sector. Aggressive investors have been buying the Direxion Daily S&P Biotech Bull 3X Shares ETF LABU.

This ETF seeks the daily investment results, before fees and expenses, of 300% of the performance of the S&P Biotechnology Index for a single day.

See Also: 5 Biogen Analysts On FDA Approval Of Alzheimer's Drug Aduhelm, Broad Label, Pricing

If the index continues to move higher, LAU should move by about three times as much. But it goes the other way, too, and investors need to exercise caution. If the index heads south, LABU will fall by about three times as much.


Market News and Data brought to you by Benzinga APIs
Posted In: BiotechSector ETFsSpecialty ETFsTrading IdeasETFsGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!